OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
metadata only
Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort
Background: Erb-b2 receptor tyrosine kinase 2 (ERBB2)-activating mutations are well-documented oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in approximately 1–4% of cases. These alterations include a heterogeneous spectrum of variant subtypes; however, the clinicogenomic charac
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer#1128030
- GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer#855772
- Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer#1295401
- Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2#804642
- Erlotinib for Hepatocellular Carcinoma Chemoprevention#1111700
Record · ID 1347138
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive